Imunon, Inc. (NASDAQ:IMNN – Get Free Report) CEO Stacy Lindborg bought 25,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were purchased at an average price of $0.98 per share, for a total transaction of $24,500.00. Following the completion of the purchase, the chief executive officer now directly owns 264,166 shares of the company’s stock, valued at approximately $258,882.68. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Imunon Price Performance
Imunon stock opened at $1.08 on Friday. The stock has a market cap of $10.11 million, a PE ratio of -0.50 and a beta of 2.12. The stock’s fifty day moving average is $1.25 and its two-hundred day moving average is $1.16. Imunon, Inc. has a 1-year low of $0.48 and a 1-year high of $3.65.
Imunon (NASDAQ:IMNN – Get Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05. On average, research analysts expect that Imunon, Inc. will post -2.09 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Research Report on Imunon
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Recommended Stories
- Five stocks we like better than Imunon
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Lockheed Martin’s Sky-High Surge: Buy Now or Wait for a Landing?
- Consumer Discretionary Stocks Explained
- Deere Rebounds on Earnings Beat, But Uphill Battle Remains
- What is the NASDAQ Stock Exchange?
- Mutual Funds vs Hedge Funds: What’s the Difference?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.